¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"stem cell growth factors"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • acantholytic cell
    °¡½Ã¼¼Æ÷ºÐ¸®¼¼Æ÷
  • angioimmunoblastic T-cell lymphoma
    Ç÷°ü¸é¿ª¸ð±¸T¼¼Æ÷¸²ÇÁÁ¾
  • annular elastotic giant cell granuloma
    °í¸®Åº·Â¼¶À¯°Å´ë¼¼Æ÷À°¾ÆÁ¾, ȯ»óź·Â¼¶À¯°Å´ë¼¼Æ÷À°¾ÆÁ¾
  • accessory cell
    º¸Á¶¼¼Æ÷, µ¡¼¼Æ÷
  • antibody-dependent cell-mediated cytotoxicity
    Ç×üÀÇÁ¸¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º
  • antibody-producing cell
    Ç×ü»ý»ê¼¼Æ÷
  • antibody-screening cell
    Ç×ü¼±º°Ç÷±¸
  • antigen-presenting cell
    Ç׿øÁ¦½Ã¼¼Æ÷
  • antigen-reactive cell
    Ç׿ø¹ÝÀÀ¼¼Æ÷
  • antigen-recognizing cell
    Ç׿øÀÎÁö¼¼Æ÷
  • argentaffin cell
    ÀºÄ£È­¼¼Æ÷
  • argyrophilic cell
    ÀºÄ£È­¼¼Æ÷
  • asexual cell
    ¹«¼º¼¼Æ÷
  • acidophilic cell
    È£»ê¼¼Æ÷
  • acinar cell
    »ù²Ê¸®¼¼Æ÷, ¼¼¿±¼¼Æ÷
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • sickle cell trait
    ³´¼¼Æ÷¼ÒÁú, ³´ÀûÇ÷±¸Çü¼º¼ÒÁú
  • packed cell volume
    ÃæÀü¼¼Æ÷¿ëÀû, ³óÃ༼Æ÷¿ëÀû
  • red cell distribution width
    ÀûÇ÷±¸ºÐÆ÷Æø
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • specific growth rate
    ƯÀÌÁõ½Ä·ü
  • acantholytic cell
    °¡½Ã¼¼Æ÷ÇØ¸®¼¼Æ÷
  • accessory cell
    º¸Á¶¼¼Æ÷, µ¡¼¼Æ÷
  • acidophilic cell
    È£»ê¼º¼¼Æ÷
  • acinar cell
    »ù²Ê¸®¼¼Æ÷
  • acinic cell carcinoma
    »ù²Ê¸®¼¼Æ÷¾ÏÁ¾, ¼¼¿±¼¼Æ÷¾ÏÁ¾
  • amacrine cell
    ¹«Ãà»è¼¼Æ÷
  • ameboid cell
    ¾Æ¸Þ¹Ù¸ð¾ç¼¼Æ÷
  • annular elastotic giant cell granuloma
    °í¸®Åº·Â¼¶À¯°Å´ë¼¼Æ÷À°¾ÆÁ¾, ȯ»óź·Â¼¶À¯°Å´ë¼¼Æ÷À°¾ÆÁ¾
  • antibody-dependent cell-mediated cytotoxicity
    Ç×üÀÇÁ¸¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º
  • antibody-producing cell
    Ç×ü»ý»ê¼¼Æ÷
  • antibody-screening cell
    Ç×ü¼±º°Ç÷±¸
  • antigen-presenting cell
    Ç׿øÀü´Þ¼¼Æ÷
  • antigen-reactive cell
    Ç׿ø¹ÝÀÀ¼¼Æ÷
  • antigen-recognizing cell
    Ç׿øÀÎÁö¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • growth line
    ¼ºÀå¼±(¡­àÊ).
  • growth of jaw
    ¾Ç¼ºÀå.
  • growth onset type diabetes
    Ãʱâ´ç´¢º´.
  • growth period
    ¼ºÀå±â(à÷íþÑ¢).
  • growth plate
    ¼ºÀåÆÇ(à÷íþη)
  • growth promotant
    ¼ºÀåÃËÁøÁ¦.
  • growth promoting factor
    ¼ºÀåÃËÁøÀÎÀÚ(à÷íþõµòäì×í­), ¹ßÀ°ÃËÁø¹°Áú(Û¡ëÀõµòäÚªòõ)
  • growth quotient
    ¼ºÀåÁö¼ö(à÷íþò¦â¦), ¹ßÀ°Áö¼ö(Û¡ëÀò¦â¦).
  • growth rate
    ¼ºÀå·ü(ËÛËöËô).
  • growth rate constant
    Áõ½Ä·ü»ó¼ö
  • growth regulator
    ¼ºÀåÁ¶ÀýÀÎÀÚ.
  • growth retardation
    ¼ºÀåÁö¿¬.
  • hair growth
    ¸ð(¹ß)¼ºÀå
  • hematopoietic growth factor
    Á¶Ç÷¼ºÀåÀÎÀÚ
  • hepatocyte growth factor
    °£¼¼Æ÷¼ºÀåÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • cycle, growth
    Áõ½ÄÁÖ±â
  • developmental disease =growth abnor mal ity
    ¹ß´ÞÀÌ»ó(¡­ì¶ßÈ).
  • economic growth
    °æÁ¦¼ºÀå.
  • epidermal growth factor
    Ç¥ÇǼºÀåÀÎÀÚ
  • epidermal growth factor
    Ç¥ÇǼºÀåÀÎÀÚ(øúù«à÷íþì×í­)
  • epidermal growth factor
    Ç¥ÇǼºÀå ÀÎÀÚ(¡­à÷íþ ì×í­)
  • epidermal growth factor (EGF)
    ÇǺÎÁõ½ÄÀÎÀÚ
  • epidermal growth factor = EGF
    Ç¥ÇÇ ¼ºÀå ÀÎÀÚ
  • epidermoid growth factor
    Ç¥ÇÇ¾ç ¼ºÀåÀÎÀÚ(¡­à÷íþì×í­)
  • essential growth factor
    ÇʼöÁõ½ÄÀÎÀÚ
  • excessive growth
    ¼ºÀå°úµµ
  • exponential growth
    Áö¼öÁõ½Ä.
  • exponential growth phase
    Áö¼öÁõ½Ä±â(ÊÙÌ¡ËàË»).
  • exponential growth rate
    ´ë¼öÁõ½Ä·ü, Áö¼öÁõ½Ä·ü
  • exponential phase of growth
    ´ë¼öÁõ½Ä±â, °¡¼Ó¼ºÀå±â.
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • Stellate myoepithelial cell
    º°±ÙÀ°»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ¼º»ó±Ù»óÇǼ¼Æ÷
  • Stellate cell
    º°¼¼Æ÷
    [¿¾ ¿ë¾î] ¼º»ó¼¼Æ÷
  • Cell of parathyroid gland
    ºÎ°©»ó»ù¼¼Æ÷
    [¿¾ ¿ë¾î] ºÎ°©»ó¼±¼¼Æ÷
  • Secretory synovial cell
    ºÐºñÀ±È°¼¼Æ÷
    [¿¾ ¿ë¾î] Ȱ¸·ºÐºñ¼¼Æ÷
  • Mast cell
    ºñ¸¸¼¼Æ÷
    [¿¾ ¿ë¾î] ºñ¸¸¼¼Æ÷
  • Intercalated epithelial cell
    »çÀÌ»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] Áß°£Ãþ»óÇǼ¼Æ÷
  • Interstitial cell
    »çÀÌÁú¼¼Æ÷
    [¿¾ ¿ë¾î] °£Áú¼¼Æ÷
  • Epithelial reticular cell
    »óÇǼ¼¸Á¼¼Æ÷
    [¿¾ ¿ë¾î] »óÇǼº¼¼¸Á¼¼Æ÷
  • Pigment epithelial cell
    »ö¼Ò»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] »ö¼Ò»óÇǼ¼Æ÷
  • Glandular cell
    »ù¼¼Æ÷
    [¿¾ ¿ë¾î] ¼±¼¼Æ÷
  • Ciliated ependymal cell
    ¼¶¸ð³ú½Ç¸·¼¼Æ÷
    [¿¾ ¿ë¾î] ¼¶¸ð»óÀǼ¼Æ÷
  • Ciliated epithelial cell
    ¼¶¸ð»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ¼¶¸ð»óÇǼ¼Æ÷
  • Ciliated cell
    ¼¶¸ð¼¼Æ÷
    [¿¾ ¿ë¾î] ¼¶¸ð¼¼Æ÷
  • Apex of cell
    ¼¼Æ÷²À´ë±â
    [¿¾ ¿ë¾î] ¼¼Æ÷÷
  • Cell membrane
    ¼¼Æ÷¸·
    [¿¾ ¿ë¾î] ¼¼Æ÷¸·
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • cytotoxic T cell
    ¼¼Æ÷µ¶¼º(á¬øàÔ¸àõ) T ¼¼Æ÷(á¬øà)
  • double-sector cell
    ÀÌÁß±¸È¹½Ç(ì£ñìÏ¡üñãø)
  • effector cell
    È¿°ú±â ¼¼Æ÷(üùÍýÐïá¬øà)
  • enucleated cell
    Á¦ÇÙ ¼¼Æ÷ (ð¶ú·á¬øà)
  • established cell line
    ¼ö¸³ ¼¼Æ÷ÁÖ (â§Ø¡á¬øàñ»)
  • feeder cell
    °ø±ÞÀÚ¼¼Æ÷ (ÍêÐåíºá¬øà)
  • flow cell
    È帧 ½Ç(ãø)
  • founder cell
    ½ÃÁ¶ ¼¼Æ÷(ã·ðÓá¬øà)
  • germ cell
    ¹è¼¼Æ÷(ÛÏá¬øà)
  • germinal cell
    ¹è¾Æ¼¼Æ÷(ÛÏä´á¬øà)
  • glial cell
    ½Å°æ±³¼¼Æ÷(ãêÌèÎïá¬øà)
  • half-cell
    ¹Ý½Ç(Úâãø)
  • helper T cell
    µµ¿òÀÌ T ¼¼Æ÷(á¬øà)
  • host-cell reactivation
    ¼÷ÁÖ ¼¼Æ÷ ÀçȰ¼ºÈ­(âÖñ«á¬øàî¢üÀàõûù)
  • hybrid cell
    Æ¢±â¼¼Æ÷(á¬øà)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
HFD hemorrhagic fever of deer; high-fiber diet; high forceps delivery; hospital field director; human fa...
PF1-4 platelet factors 1 to 4
PQRST provocative and palliative factors, quality of pain, radiation of pain, severity of pain, timing of ...
PULSES physical condition, upper limb function, lower limb function, sensory component, excretory function,...
GC ganglion cell; gas chromatography; general circulation; general closure; general condition; generali...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
PSCA Prostate Stem Cell Antigen
rhSCF Recombinant human stem cell factor
SCF Stem Cell Factor
SCT Stem cell transplantation
ASCR autologous stem cell rescue
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • B cell stimulating factor 1
    B ¼¼Æ÷ ÃËÁø ÀÎÀÚ 1
    µ¿ÀǾî´Â Interleukin 4·Î ¾Ë·ÁÁø ´ç´Ü¹éÀ¸·Î¼­ T ¼¼Æ÷, ºñ¸¸¼¼Æ÷ µî¿¡¼­ »ý»êµÈ´Ù. À̰ÍÀº B ¼¼Æ÷¿¡ ´ëÇØ comitogenÀ¸·Î ÀÛ¿ëÇϴµ¥ ±× ¿µÇâÀº B ¼¼Æ÷ÀÇ ¼º¼÷µµ¿¡ µû¶ó ´Ù¸£´Ù.
  • B cell tolerance
    B ¼¼Æ÷ ³»¼º
    ¸é¿ªÇÐÀû ³»¼º »óÅ´ T ¼¼Æ÷¿¡µµ B ¼¼Æ÷¿¡µµ ¹ß»ý ¼ö ÀÖÁö¸¸ B ¼¼Æ÷ÀÇ ³»¼º »óÅ´ T ¼¼Æ÷¿¡ ºñÇÏ¿© ¹ß»ýÇϱⰡ ¾î·Æ´Ù. B ¼¼Æ÷¸¦ ³»¼º »óÅ·ΠÇÏ·Á¸é ÀϹÝÀûÀ¸·Î ´ë·®ÀÇ Ç׿øÀÌ ÇÊ¿äÇϰí Ç׿ø Åõ¿© ÈÄ¿¡ ³»¼º »óÅ·Πµé¾î°¡´Â µ¥µµ T ¼¼Æ÷º¸´Ù ¿À·£ ½Ã°£ÀÌ °É¸®°í ÀÏ´Ü ³»¼º »óÅ·Πµé¾î°¡µµ Áö¼Ó½Ã°£ÀÌ Âª°í °ð ÇØÁ¦µÇ¾î ¹ö¸°´Ù.
  • band cell
    ¶ì ¼¼Æ÷
  • basal cell
    ±âÀú ¼¼Æ÷, ±âÃÊ ¼¼Æ÷
    Ç¥ÇÇ ±âÀúÃþ¿¡ Á¸ÀçÇÏ´Â Ãʱâ ÄÉ¶óÆ¾ ¼¼Æ÷¸¦ ÀÏÄ´ À̸§. Æ÷À¯·ù Á¤¼ÒÀÇ ¼¼Á¤°ü ¼Ó¿¡¼­ ¿ÜÃø ±âÀú¸·¿¡ Á¢ÇÏ¿© »êÀçÇØ ÀÖ´Â ´ëÇü ¼¼Æ÷. ¼¼¸£Å縮 ¼¼Æ÷
  • basal cell adenocarainoma
    ±âÀú ¼¼Æ÷ ¼±¾Ï
    ¸Å¿ì µå¹°°í ±âÀú ¼¼Æ÷ ¼±Á¾ÀÇ ¾Ç¼ºÀÌ´Ù. ¿Ü°úÀû ÀýÁ¦ ½Ã ¿¹Èİ¡ ÁÁ´Ù.
  • basal cell carcinoma
    ±âÀú ¼¼Æ÷ ¾Ï, ±âÀú ¼¼Æ÷ ¾ÏÁ¾
    1. »óÇÇÀÇ ±âÀú ¼¼Æ÷¸¦ ´àÀº ±âº» ±¸Á¶¸¦ °¡Áö´Â »óÇÇ ¼¼Æ÷ ½Å»ý¹°. À̰ÍÀº »óÇÇ ¼¼Æ÷ÀÇ ±âÀú ¼¼Æ÷, ¸ð³¶À̳ª ÇÇÁö¼±ÀÇ ¿Ü¹æ ¼¼Æ÷, ƯÈ÷ ¾È¸éÀÇ °¡¿îµ¥ 1/3¿¡¼­ ¹ß»ýÇÑ´Ù. µå¹°°Ô ÀüÀ̵ÇÁö¸¸ ±¹¼ÒÀûÀ¸·Î ħ¹üÇÑ´Ù. ±¸°­ Á¡¸·¿¡¼­´Â ¹ß»ýÇÏÁö ¾Ê´Â´Ù. Çѱ¹ÀÎ ÇǺΠ¾Ç¼º Á¾¾ç Áß °¡Àå ¸¹Àº ÇüÀÌ´Ù. ÀüÀ̰¡ Àß ¾ÈµÇ¸ç Àç¹ßÀ²ÀÌ ÀûÀº Áß°£ ¾Ç¼ºµµÀÌ´Ù. ±¸°­ÀÇ ±âÀú ¼¼Æ÷ ¸ð¹Ý ÁõÈıº°ú °ü·ÃÀÌ ÀÖ´Ù. 2. Ç¥ÇÇ ±âÀúÃþÀÇ ¾Ç¼º Á¾¾ç.
  • basal cell epithelioma
    ±âÀú ¼¼Æ÷ »óÇÇ ¾Ï, ±âÀú ¼¼Æ÷ »óÇÇÁ¾
    Áß³â ÀÌÈÄ¿¡ »ý±â±â ½±°í ±× ŹÝÀÌ ¾È¸é ÇǺο¡ ¹ß»ýÇÑ´Ù. Ãø»öÀÇ ¼Ò°áÀýÀÌ Áý»êÇÑ Á¾¾çÀ» Çü¼ºÇϴµ¥ ¹Ý±¸»óÀ¸·Î À¶±âÇÏ´Â °Í, ÆíÆòÇÑ ¹Ý»óÀÇ ÆÛÁü µî ¿©·¯ °¡ÁöÀÌ´Ù. Á¶Á÷ÇÐÀûÀ¸·Î´Â ÇǺΠǥÇÇ ±âÀú ¼¼Æ÷ÀÇ Áõ½ÄÀÌ°í ¼¼Æ÷ ºÐ¿­, ÀÌÇü¼º µîÀº °ÅÀÇ ³ªÅ¸³ªÁö ¾Ê´Â´Ù.
  • basal cell hyperplasia
    ±âÀú ¼¼Æ÷ °úÇü¼º
  • basal cell nevus
    ±âÀú ¼¼Æ÷ ¸ð¹Ý
  • basal cell papilloma
    ±âÀú ¼¼Æ÷ À¯µÎÁ¾
  • basal-cell layer
    ±âÀú ¼¼Æ÷Ãþ
  • basophilic cell
    È£¿°±â¼º ¼¼Æ÷
  • basosqumaous cell acanthoma
    ±âÀú ÆíÆò ¼¼Æ÷ ±Ø¼¼Æ÷Á¾
  • benign giant cell tumor
    ¾ç¼º °Å´ë¼¼Æ÷ Á¾¾ç
    1. °ñÀÇ ¾ç¼º °Å´ë¼¼Æ÷Á¾. °ñÀÇ ¾ç¼º Á¾¾çÀÇ Çϳª·Î ³ë¾àÀÚ¿¡°Ô ¸¹À¸¸ç ¹ß»ý ºÎÀ§´Â Àå°ü°ñÀÇ °ñ´Ü¿¡ ¸¹ÀÌ ³ªÅ¸³­´Ù. Á¶Á÷ÇÐÀûÀ¸·Î ¿øÇü, ¹æÃßÇüÀÌ ÀÖ´Ù. ¼¼Æ÷ »çÀÌ¿¡ ÆÄ°ñ¼¼Æ÷¿Í À¯»çÇÑ °Å´ë¼¼Æ÷°¡ È¥ÀçÇÑ´Ù. 2. °ÇÃÊÀÇ ¾ç¼º °Å´ë¼¼Æ÷Á¾. º»·¡ Á¾¾çÀÌ ¾Æ´Ï¸ç, °áÁ¤¼º °ÇÃÊ¿°À» °¡¸®Å°¸ç °ÇÃÊÀÇ ¼¶À¯¼º Á¶Á÷±¸Á¾¿¡ Æ÷ÇԵȴÙ.
  • beta cell tumor
    º£Å¸ ¼¼Æ÷Á¾
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
transcription factors, tfii The so-called general transcription factors that bind to RNA polymerase II and that are required to initiate transcription. They include tfiia, tfiib, tfiid, tfiie, tfiif, tfiih, tfii-I, and tfiij. In vivo they apparently bind in an ordered multi-step process and/or may form a large preinitiation complex called RNA polymerase II holoenzyme.
(12 Dec 1998)
transcription factors, tfiii Factors that bind to RNA polymerase III and aid in transcription. They include the assembly factors tfiiia and tfiiic and the initiation factor tfiiib. All combine to form a preinitiation complex at the promotor that directs the binding of RNA polymerase III.
(12 Dec 1998)
epidemiologic factors Events, characteristics, or other definable entities that have the potential to bring about a change in a health condition or other defined outcome.
(12 Dec 1998)
essential food factors Those substances required in the diet: certain amino acids and unsaturated fatty acids, vitamins, essential minerals, etc.
(05 Mar 2000)
Factors I XII <haematology> Blood clotting factors, especially from humans. These factors form a cascade in which the activation of the first factor leads to enzymic attack on the next factor and so on, finally resulting in blood clotting.
(18 Nov 1997)
uncoupling factors Substances such as dinitrophenol that allow oxidation in mitochondria to proceed without the usual concomitant phosphorylation to produce ATP; these poisons thus "uncouple" oxidation and phosphorylation.
Synonym: uncoupling factors.
(05 Mar 2000)
lactose factors Plasmids which determine the ability of a bacterium to ferment lactose.
(12 Dec 1998)
LE factors Antinuclear immunoglobulins in plasma of persons with disseminated lupus erythematosus, associated with positive LE tests.
(05 Mar 2000)
leukocyte migration-inhibitory factors Protein factor(s) released by sensitised lymphocytes (and possibly other cells) that inhibit the movement of leukocytes, especially polymorphonuclear cells, away from their site of release. Assays for these factors are used as tests for cellular immunity. Two of the common assays are the leukocyte migration capillary tube technique (lmct) and the leukocyte migration agarose technique (lmat).
(12 Dec 1998)
T-cell-rich, B-cell lymphoma <tumour> A B-cell lymphoma in which more than 90% of the cells are of T-cell origin, masking the large cells that form the neoplastic B-cell component.
See: adult T-cell lymphoma.
(05 Mar 2000)
accretionary growth Growth by an increase of intercellular material.
(05 Mar 2000)
appositional growth Growth accomplished by the addition of new layers on those previously formed; e.g., the addition of lamellae in the formation of bone; it is the characteristic method of growth when rigid materials are involved.
(05 Mar 2000)
auxetic growth Growth by increase in the size of component cells.
Synonym: intussusceptive growth.
(05 Mar 2000)
bacterial growth Growth of a bacterial culture either by increase in cell material or cell number.
(05 Mar 2000)
biphasic growth curve <cell culture, microbiology> A particular type of growth curve seen in cultured microorganisms in which they have two exponential growth stages separated by a plateau phase. This double-hump curve is produced when the microbes are cultured using two carbon sources, one of which must be used up before the second can be used.
(19 Jan 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
ÅëÇÕ°Ë»ö ¿Ï·á